“Elsevier officials said Monday that it was a mistake for the publishing giant’s marketing division to offer $25 Amazon gift cards to anyone who would give a new textbook five stars in a review posted on Amazon or Barnes & Noble. While those popular Web sites’ customer reviews have long been known to be something less than scientific, and prone to manipulation if an author has friends write on behalf of a new work, the idea that a major academic publisher would attempt to pay for good reviews angered some professors who received the e-mail pitch.”
I sometimes get a case of schadenfreude reading about bad things that happen to big companies that have a hand in library businesses. This latest mess involves Elsevier publishing what can charitably called a “sponsored journal” and what can uncharitably be called a fake scam journal, sponsored by Merck and internded solely to be cited in support of their drug Fosamax. If anyone has ongoing dealings with Elsevier and would like to get across to them how uncool this is, I’d appreciate it. Original article published at TheScientist.com available here with free registration. [nowthis]
Elsevier acknowledged that Merck had sponsored the publication, but did not disclose the amount the drug company paid. In a statement emailed to The Scientist, Elsevier said that the company “does not today consider a compilation of reprinted articles a ‘Journal’.”
“Elsevier acknowledges the concern that the journals in question didn’t have the appropriate disclosures,” the statement continued. “It is worth noting that project in question was produced 6 years ago and disclosure protocols have evolved since 2003. Elsevier’s current disclosure policies meet the rigor and requirements of the current publishing environment.”
The Elsevier spokesperson said the company wasn’t aware of how many copies of the Australasian Journal of Bone and Joint Medicine were produced or how the publication was distributed in Australia, but noted that “the common practice for sponsored journals is that doctors receive them complimentary.” The spokesperson added that Elsevier had no plans to look further into the matter.